DrugBank ID: db00065
DrugCentral: infliximab
Synonymous :infliximab (genetical recombination) | infliximab-abda | infliximab-axxq | infliximab-dyyb | infliximab-qbtx

Drug Sentece Context

Table 1. Analysis of context sentence of infliximab gene in 9 abstracts.

pmid sentence
32452979 The patient was treated with infliximab for TNF-α blockade to address both moderately to severely active Crohn’s disease and multisystem inflammatory syndrome in children (MIS-C) temporally related to COVID-19. […] Within hours of infliximab treatment, fever, tachycardia and hypotension resolved.
32513653 In patients requiring rescue therapy, infliximab with continuing steroids was recommended.
32618402 Infliximab patients and the one with serious comorbidities showed the worst outcome.
32696108 Specific immune modulators include anti-cytokines such as interleukin (IL)-1 and IL-6 receptor antagonists (e.g. anakinra, tocilizumab, sarilumab, siltuximab), Janus kinase (JAK) inhibitors (e.g. baricitinib, ruxolitinib), anti-tumor necrosis factor-α (e.g. adalimumab, infliximab), granulocyte-macrophage colony-stimulating factors (e.g. gimsilumab, lenzilumab, namilumab), and convalescent plasma, with promising to negative trials and other data.
32738060 During the one month after COVID-19 outbreak, 39 (39/56, 69.6%) patients had their infliximab infusion postponed with the mean delay of 3 weeks.
32873696 In patients requiring second-line therapy, infliximab was considered appropriate irrespective of SARS-CoV-2 status. […] Our COVID-19-specific adaptations to paediatric ASC guidelines using a RAND panel generally support existing recommendations, particularly the use of corticosteroids and escalation to infliximab, irrespective of SARS-CoV-2 status.
32891582 Treatment strategies included intravenous immunoglobulin (63%) and intravenous steroids (44%). 29 cases received Infliximab, 47 received IL1 (interleukin) receptor antagonist, and 47 received IL6-receptor antagonist.
32956615 These include IL-1 antagonists (eg, anakinra), IL-6 receptor blockers (eg, tocilizumab), and anti-TNF agents (eg, infliximab) for children with Kawasaki disease-like phenotype and non-specific presentations.
32997749 We report the first case of PIMS-TS in a child on established anti-Tumor Necrosis Factor-alpha (anti-TNF-α) therapy; a 10 year-old girl with ulcerative colitis treated with infliximab. […] Infliximab treatment followed and the patient has remained well at follow up. […] Given the uncertainty around therapeutic strategies for PIMS-TS this case supports the need for further investigation into continuing infliximab as a treatment option for the condition.
32999889 We report the case of an 18-year-old ulcerative colitis patient in sustained clinical remission who 4 days after application of her ongoing therapy with the anti-TNF antibody infliximab developed mild respiratory and abdominal symptoms.